PA
SWTX

Pinnacle Associates’s SpringWorks Therapeutics SWTX Stock Holding History

Pinnacle Associates’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,920
Closed -$261K – 845
2024
Q2 		$261K Hold
6,920
– – ﹤0.01% 722
2024
Q1 		$341K Buy
+6,920
New +$320K 0.01% 669

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Pinnacle Associates's SWTX Position: Q3 2024 in Review

Pinnacle Associates sold out of SpringWorks Therapeutics (SWTX) in Q3 2024, closing a stake of 6,920 shares — an estimated $261K sold.

Pinnacle Associates first reported a position in SWTX in Q1 2024 and held it in 2 quarters. The position peaked at $341K in Q1 2024. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

  • Pinnacle Associates reported no remaining SpringWorks Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pinnacle Associates sold 6,920 SpringWorks Therapeutics shares in Q3 2024, an estimated $261K.
  • Pinnacle Associates first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 2 quarters.
  • Pinnacle Associates's SpringWorks Therapeutics position peaked at $341K in Q1 2024.
  • 226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on Pinnacle Associates's 13F filing for Q3 2024, filed 25 Oct 2024.